Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34473259 | 0.93 | OPRM1 (0.46) | OPRM1SIGMAR1CHRM2CHRM3KCNH2 | |
| SCHEMBL9653047 | 0.87 | OPRM1 (0.53) | OPRM1SIGMAR1CHRM2CHRM3ACHE | |
| SCHEMBL7705091 | 0.85 | OPRM1 (0.45) | OPRM1SIGMAR1CHRM2CHRM3KCNH2 | |
| SCHEMBL803672 | 0.84 | SIGMAR1 (0.59) | OPRM1SIGMAR1CHRM2CHRM3KCNH2 | |
| SCHEMBL1205295 | 0.82 | ACHE (0.45) | OPRM1SIGMAR1CHRM2CHRM3ACHE | |
| SCHEMBL2494975 | 0.81 | OPRM1 (0.57) | OPRM1SIGMAR1CHRM2CHRM3KCNH2 | |
| SCHEMBL34473195 | 0.80 | HSD11B1 (0.48) | OPRM1SIGMAR1CHRM2CHRM3KCNH2 | |
| SCHEMBL34473196 | 0.80 | HSD11B1 (0.48) | OPRM1SIGMAR1CHRM2CHRM3KCNH2 | |
| SCHEMBL7507555 | 0.80 | SIGMAR1 (0.51) | OPRM1SIGMAR1KCNH2ACHEDRD2 | |
| SCHEMBL3815654 | 0.80 | SIGMAR1 (0.51) | OPRM1SIGMAR1KCNH2ACHEDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030502-B2 | Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects | THERAVANCE, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080091034-A1 | Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds | THERAVANCE, INC. | 2008-04-17 | — | — | US | disclosed |
| CN-100364990-C | Substituted 4-amino-1- (pyridylmethyl) piperidines and related compounds | THERAVANCE INC (US) | 2008-01-30 | — | — | CN | disclosed |
| US-7285564-B2 | Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds | THERAVANCE, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1556372-B1 | SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL) PIPERIDINE AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1680416-A2 | NAPHTHALENE-1,5-DISULFONIC ACID SALTS OF A SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL)PIPERIDINE COMPOUND | Theravance, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| CN-1708494-A | Substituted 4-amino-1- (pyridylmethyl) piperidines and related compounds | THERAVANCE INC (US) | 2005-12-14 | — | — | CN | disclosed |
| US-20050113413-A1 | Naphthalene-1,5-disulfonic acid salts of a substituted 4-amino-1-(pyridylmethyl)piperidine compound | THERAVANCE, INC. | 2005-05-26 | — | — | US | disclosed |
| WO-2005042514-A2 | NAPHTHALENE-1,5-DISULFONIC ACID SALTS OF A SUBSTITUTED 4-AMINO-1-(PYRIDYLMETHYL)PIPERIDINE COMPOUND | THERAVANCE, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20040122014-A1 | Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113413-A1 | Naphthalene-1,5-disulfonic acid salts of a substituted 4-amino-1-(pyridylmethyl)piperidine compound | CHRM1, NPSR1, CHRM3 | OPRM1 194/4885SIGMAR1 88/4885CHRM2 7/4885 |
| US-20040122014-A1 | Muscarinic M2 receptor antagonists; such as 4-{N-[7-(3-1-carbamoyl-1,1-diphenylmethyl)pyrrolidin-1-yl)hept-1-yl]-N-(isopropyl)amino}-1-(4-methoxypyrid-3-ylmethyl)piperidine; reduced blurred vision, constipation and dry mouth side effects | CHRM2, CHRM1, CHRM3 | OPRM1 18/4885SIGMAR1 246/4885CHRM2 1/4885 |
| US-20080091034-A1 | Substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds | CHRM5, CHRM1, CHRM3 | OPRM1 48/4885SIGMAR1 307/4885CHRM2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.